- 4basebio
- 20 May 2026 15:15:20
Source: Sharecast
The AIM-listed synthetic DNA specialist said the multi-year agreement was expected to generate an approximate seven-figure revenue stream over the next 12 months.
Under the deal, 4basebio will supply synthetic DNA as a critical material for the client’s immunotherapy candidate ahead of an upcoming Phase II trial.
The company said the agreement reflected growing commercial momentum and demonstrated the use of its enzymatically produced opDNA technology as a safer and cost-effective replacement for plasmid DNA in genetic medicines development.
4basebio said its enzymatic, cell-free manufacturing process would allow the client to fully eliminate microbial contamination and antibiotic resistance genes, supporting safety and helping accelerate development timelines from sequence to clinic.
Chief executive Amy Walker said the partnership showed how 4basebio’s DNA technology platform could help clients overcome complex manufacturing challenges and bring safer and effective therapies to patients.
“We continue to see growing interest in our DNA molecules across the genetic medicine space and are delighted to support our partners through their clinical trials,” she said.
At 1224 BST, shares in 4basebio were down 0.22% at 444p.
Reporting by Josh White for Sharecast.com.
See latest RNS on Investegate